|Bid||2.71 x 1000|
|Ask||6.00 x 1000|
|Day's range||3.1400 - 3.2500|
|52-week range||2.5100 - 10.4390|
|Beta (3Y monthly)||N/A|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Ltd. (ASLN) reported positive data Monday from a Phase 1b/2 trial of its varlitinib drug in combination with chemotherapy in first-line biliary tract cancer. The company said the responses in the trial were “impressive,” and that the drug has been well tolerated in biliary tract cancer patients. On Sunday, Aslan said a phase 2 combining varlitinib with mFOLFOX6 in gastric cancer patients didn’t meet its primary endpoint.
ASLAN's (ASLN) varlitinib is unable to show any statistical significance for the primary endpoint in a phase II study with regard to first-line treatment of advanced or metastatic gastric cancer.